Oxlumo market report projects growth through 2035

The Business Research Company has released a 2026 Oxlumo market report that forecasts continued expansion through 2035, driven by genetic testing, personalized medicine and rare disease treatment demand. North America led the market in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - The Oxlumo market is tied to treatment for primary hyperoxaluria type 1, a rare inherited kidney disorder that can lead to kidney stones and kidney failure. - Growth in the market reflects broader demand for targeted therapies, genetic diagnostics and personalized medicine in rare disease care. - The report points to expanding opportunities for RNA-based therapies and precision nephrology treatments.

What happened: - The Business Research Company published its Oxlumo Market Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on Nov. 9, 2026. - The report says the Oxlumo market grew in the prior period and is expected to expand further through 2035. - The report includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, and updated graphics and tables. - The report also covers North America, Western Europe, Eastern Europe, South America, the Middle East and Africa. - A free sample is available here. - The full report is available here.

The details: - Oxlumo, with the generic name lumasiran, is a treatment for primary hyperoxaluria type 1. - The therapy is administered as a subcutaneous injection. - The drug works by blocking the enzyme HOGA1, which is central to oxalate formation, reducing oxalate levels in the body. - Oxlumo is used to help prevent kidney stones and kidney failure by controlling oxalate buildup. - The market’s past growth was supported by enhanced genetic screening, limited earlier treatment options, progress in RNA-based therapeutics, higher rare disease awareness and orphan-drug approvals. - Future growth drivers include a broader pipeline of gene-silencing therapies, more rare disease investment, wider acceptance of precision nephrology, expanded access to genetic diagnostics and better long-term disease management. - Forecasted trends include increased uptake of RNA interference therapies, stronger focus on genetic kidney disorders, greater use of precision medicine for rare conditions, more subcutaneous targeted treatments and improved monitoring of metabolic disease progression. - Personalized medicine is a major driver because it aligns treatment with a patient’s genetic profile, lifestyle and environment. - The Personalized Medicine Coalition reported in February 2024 that the FDA approved 16 new personalized treatments for rare diseases in 2023, up from six in 2022. - Rising primary hyperoxaluria prevalence is also supporting demand. - Kidney Care UK said in October 2024 that hyperoxaluria affects roughly 1 in 500,000 people in the UK, with PH1 accounting for 80% of cases. - The National Center for Biotechnology Information estimated in October 2023 that PH1 prevalence in Europe ranges from 1 to 3 cases per million people.

Between the lines: - The report frames Oxlumo as part of a broader shift toward precision treatments for rare genetic diseases. - The strongest growth story appears to be less about broad population medicines and more about specialized therapies supported by better diagnosis. - North America’s lead suggests established reimbursement, infrastructure and adoption support the market today, while Asia-Pacific’s faster growth points to expanding access and testing.

What’s next: - The market is expected to keep growing as genetic testing becomes more available and rare disease pipelines deepen. - Asia-Pacific is forecast to be the fastest-growing region during the forecast period. - The report’s focus on future trends suggests more competition around RNA interference, subcutaneous delivery and long-term monitoring tools.

The bottom line: - Oxlumo’s market outlook is being shaped by rare disease diagnosis, precision medicine and expanding genetic care infrastructure, with growth expected to continue through 2035.